决定异体 CAR T 细胞排斥与扩增的细胞和分子机制
Cellular and molecular mechanisms determining allogeneic CAR T cell rejection and expansion.
我们评估了11例接受单一批次cemacabtagene ansegedleucel(cema-cel)治疗的大B细胞淋巴瘤患者,cemacabtagene ansegedleucel是一种异体抗CD19 CAR T产品。
英文原题:Antigen-IL-2 CAR-enhancer drives CAR-T fate and stemness, enhancing antitumor efficacy across models independent of IL-2Rα.
这些发现提名了一个具有强大临床开发转化潜力的先导 B 细胞成熟抗原(BCMA)-IL-2 CAR-E 候选分子,并确立 IL-2R 是 CAR-E 活性的关键驱动因素。
**背景:**临床应答持久性有限仍是嵌合抗原受体(CAR)T细胞疗法的主要挑战。CAR增强子(CAR-E)将肿瘤抗原与白细胞介素2(IL-2)突变体融合,为增强CAR-T持久性和功能提供靶向策略。但尚不明确CAR-E是否适用于不同肿瘤情境及患者来源T细胞,能否预防耗竭并维持持久性;也未知CAR-E能否在预先存在T细胞的人源化小鼠中选择性扩增CAR-T,以及其疗效在何种程度上依赖IL-2Rα还是IL-2Rβ信号。传统上,IL-2Rα(CD25)与强抗肿瘤应答和记忆形成相关,但也会导致IL-2相关毒性,包括血管渗漏和优先扩增调节性T细胞。 **方法:**研究者通过工程化构建具有选择性受体亲和力的IL-2变体,系统解析CAR-E的信号需求,并在多种体内外模型中开发和测试多种CAR-E构建体。 **结果:**CAR-E活性完全不依赖IL-2Rα,却严格依赖IL-2Rβ信号。新一代节省IL-2Rα结合的CAR-E仍保持全部效力,可强效促进CAR-T扩增、持续存在及肿瘤清除;即使剂量较低,或使用既往治疗过的多发性骨髓瘤患者来源CAR-T,亦如此。这些CAR-T不仅抵抗耗竭,数月后还可再次扩增并清除肿瘤再挑战。在预先存在T细胞的人源化小鼠中,CAR-E可选择性扩增CAR-T,使其在循环T细胞群中占主导。CAR-E对CAR-T命运具有主导性影响,可覆盖肿瘤来源信号,并在不同临床前模型中诱导一致表型。 **结论:**研究提出一个具有较强转化潜力、靶向B细胞成熟抗原(BCMA)的IL-2 CAR-E候选物,并确立IL-2Rβ是CAR-E活性的关键驱动因素。结果还表明IL-2Rα并非必需,并为设计更安全、节省IL-2Rα结合的CAR-E提供机制框架。
BACKGROUND: Limited durability of clinical responses remains a major challenge in chimeric antigen receptor (CAR)-T therapy. CAR-enhancers (CAR-Es), which fuse tumor antigens to interleukin (IL)-2 muteins, provide a targeted strategy to enhance CAR-T persistence and function. It remained unclear whether CAR-Es are effective across distinct tumor contexts, when using patient-derived T cells, or in preventing exhaustion and sustaining persistence. It was also unknown whether CAR-Es can selectively expand CAR-Ts in humanized mice with pre-existing T cells, and to what extent their efficacy depends on IL-2R vs IL-2R engagement. While IL-2R (CD25) has been classically linked to potent antitumor responses and memory formation, it also drives IL-2-associated toxicities, including vascular leak and preferential regulatory T cell expansion. METHODS: We systematically dissected CAR-E signaling requirements by engineering IL-2 variants with selective receptor affinities. Multiple CAR-E constructs were developed and tested across a range of in vitro and in vivo models. RESULTS: We demonstrate that CAR-E activity is entirely independent of IL-2R and critically dependent on IL-2R signaling. A next-generation IL-2R -sparing CAR-E maintained full potency, driving robust CAR-T expansion, persistence, and tumor clearance, even at low doses and when using CAR-T cells derived from previously treated multiple myeloma patients. These CAR-T cells not only resisted exhaustion but also re-expanded months later to eradicate tumor rechallenges. In humanized mice with pre-established T cells, CAR-Es selectively expanded CAR-Ts to dominate the circulating T-cell pool. CAR-E exerted a dominant influence on CAR-T fate, overriding tumor-derived cues and enforcing consistent phenotypes across diverse preclinical models. CONCLUSIONS: These findings nominate a lead B-cell maturation antigen (BCMA)-IL-2 CAR-E candidate with strong translational potential for clinical development and establish IL-2R as a key driver of CAR-E activity. The results also identify IL-2R as dispensable and provide a mechanistic framework for designing safer, IL-2R -sparing CAR-Es.
MEMBER ACCOUNT
登录成功会直接打开下一页。